Purpose: The use of systemic corticosteroids for the management of acute exacerbation of chronic obstructive pulmonary disease (AECOPD) was studied. Methods: Medical charts of patients admitted to the ...

Even patients with mild chronic obstructive pulmonary disease (COPD) exacerbations can benefit from antibiotics and systemic corticosteroids, according to a systematic review and meta-analysis ...

A review gives an overview of potential biomarkers in chronic obstructive pulmonary disease. In a recently published review, researchers outlined the background research and results of clinical trials ...

In a retrospective analysis of patients with chronic obstructive pulmonary disease (COPD), those whose exacerbations were treated with systemic corticosteroids alone, or together with antibiotics, did ...

Please provide your email address to receive an email when new articles are posted on . Percent predicted FEV 1 did not improve after systemic corticosteroid treatment. This treatment was also not ...

Short- vs. Longer-Duration Corticosteroid Tx for COPD Exacerbations Currently, COPD guidelines recommend that patients with acute exacerbations be treated with systemic corticosteroids for 7-14 days, ...

Please provide your email address to receive an email when new articles are posted on . DALLAS — Patients with acute exacerbations of chronic obstructive pulmonary disease requiring hospitalization ...

Reviewed by Ware Kuschner, MD, Professor of Medicine, Division of Pulmonary and Critical Care Medicine, Stanford University School of Medicine Acute exacerbations of chronic obstructive pulmonary ...

Chronic obstructive pulmonary disease (COPD) treatments involving inhaled corticosteroids (ICSs) were associated with a greater risk for fractures, a meta-analysis of several dozen randomized trials ...

WILMINGTON, Del., Nov. 11, 2013 /PRNewswire/ -- For many Americans, breathing is a challenge. Over 12 million have chronic obstructive pulmonary disease (COPD) and live with symptoms, including ...

Approval based on Phase III ETHOS trial which showed a statistically significant reduction in the rate of exacerbations compared with dual-combination therapies WILMINGTON, Del.--(BUSINESS WIRE)-- ...